External broker reports(aggregated public sources), CMB International

CMB International

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>3SBio reported 1H25 revenue of RMB4.4bn, down 0.8% YoY, primarily due to a slowdown of TPIAO but partially offset by strong growth in the alopecia franchise.</li><li>During the period, attributable net profit rose 24.6% YoY to RMB1.1bn, thanks to a 49% YoY reduction in finance costs.</li><li>While legacy products remain under pressure, a number of new drugs are expected to launch in 2025–2026E, including 608 (IL-17A) and 613 (IL-1β) etc., which should help drive product sales. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

3SBio reported 1H25 revenue of RMB4.4bn, down 0.8% YoY, primarily due to a slowdown of TPIAO but partially offset by strong growth in the alopecia franchise.During the period, attributable net profit rose 24.6% YoY to RMB1.1bn, thanks to a 49% YoY reduction in finance costs.While legacy products remain under pressure, a number of new drugs are expected to launch in 2025–2026E, including 608 (IL-17A) and 613 (IL-1β) etc., which should help drive product sales. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

3SBio (1530 HK) - The Journey of Globalization Has Just Begun

3SBio Inc

3SBio (1530 HK) - The Journey of Globalization Has Just Begun